Coverage dated May 11, 2023 to May 12, 2023
Veozah, a new menopause drug for hot flashes, gets FDA approval Headline from FOX 5 New York
More than 80% of women experience hot flashes during menopause, the FDA noted.
FOX 5 New York's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Reports & sources Newest first Show outlet leaning
Filter reports by outlet or headline words
11 articles, oldest first.
KTVZ Bend
FDA greenlights a new type of drug for menopausal hot flashes ↗ (opens KTVZ Bend) Published May 11, 2023
KTVZ Bend's feed description By Brenda Goodman, CNN The US Food and Drug Administration on Friday approved a new type of drug to treat hot flashes and night sweats during menopause. Veozah, or fezolinetant, made by Astellas Pharma, is the first approved neurokinin 3 (NK3) antagonist.
FOX 5 New York
Veozah, a new menopause drug for hot flashes, gets FDA approval ↗ (opens FOX 5 New York) Published May 12, 2023
Same headline from 7 more outlets FOX 5 New York's feed description More than 80% of women experience hot flashes during menopause, the FDA noted.
New York Times
What to Know About the New Treatment for Hot Flashes ↗ (opens New York Times) Published May 12, 2023
New York Times's feed description Veozah, a nonhormonal drug, is effective against a signature symptom of menopause.
ABC 7 Chicago
FDA approves Veozah, first-of-its-kind drug to treat hot flashes ↗ (opens ABC 7 Chicago) Published May 12, 2023
ABC 7 Chicago's feed description A new menopause drug for hot flashes received FDA approval on Friday.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
